Alert detail
LCD L39005: MolDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer — Noridian
What changed
New LCD for prostate cancer biomarkers impacts billing strategies.
Who’s affected: Oncology billing teams · Effective: January 22, 2026
Primary source: View the official CMS/MAC document ↗
Get the action steps and full analysis
This change affects 9 billing codes.
The full analysis, the revision comparison and the as-of-date version of this policy are what a partner packet carries. The source document above is free and always will be.